# Situation: The nurse works in a hospital chemotherapy day unit that treats adults with solid tumors. Another client had complete surgical removal of a stage III (tumor 3, node 1, metastasis 0) colon cancer. He asks why he needs chemotherapy when all the tumor was removed. Which explanation is accurate?

> source: MyMerci (mymerci.kr)  
> url: https://mymerci.kr/pages/nclex_q.php?qn_id=629938  
> language: ko  
> subject: Nursing Practice III — Care of Clients with Problems in Surgery, Oxygenation, Fluid and Electrolytes, Infectious, Inflammatory and Immunologic Response, Cellular Aberrations

## 문제

Situation: The nurse works in a hospital chemotherapy day unit that treats adults with solid tumors.

Another client had complete surgical removal of a stage III (tumor 3, node 1, metastasis 0) colon cancer. He asks why he needs chemotherapy when all the tumor was removed. Which explanation is accurate?

## 보기

1. It replaces radiation, which the colon cannot receive
2. It prevents a new, separate polyp from forming in the colon
3. It lowers tumor markers that stay high after surgery
4. It destroys unseen cancer cells that may remain **✔ 정답**

**정답: 4**

## 해설

Stage III means the cancer had reached regional lymph nodes (N1), so cancer cells too small to detect may remain elsewhere. Adjuvant chemotherapy after surgery destroys these micrometastases and lowers the risk of recurrence.

## 심화 해설

Why adjuvant chemotherapy after complete resection of stage III colon cancer

Stage III colon cancer is defined by tumor invasion through the bowel wall and spread to regional lymph nodes (T3 N1 M0). The key word is N1: cancer cells have already traveled beyond the primary tumor into the lymphatic system. Even when the surgeon removes all visible tumor and the affected nodes, individual cancer cells or tiny clusters too small for imaging or pathology to detect may already be circulating or seeded in distant tissues. These are called micrometastases or minimal residual disease (MRD) [1][2].

Watch out! The client’s reasoning — “the tumor was completely removed, so no treatment is needed” — confuses macroscopic complete resection with microscopic cure. Surgical margins may be clear, but lymph node positivity is a marker that systemic spread has likely begun.

The purpose of adjuvant chemotherapy is not to treat visible disease; it is to eradicate occult micrometastases that remain after surgery, thereby reducing the likelihood of recurrence and potentially increasing cure rates. [1] This is why option 4 is accurate.

| Option | Why it is incorrect |
| --- | --- |
| 1. It replaces radiation, which the colon cannot receive | Radiation is not contraindicated for the colon in all cases; more importantly, the decision for chemotherapy is based on stage and nodal status, not on substituting for radiation. Adjuvant therapy for stage III colon cancer is systemic because the risk is systemic. |
| 2. It prevents a new, separate polyp from forming in the colon | Chemotherapy does not prevent new polyp formation. Polyps are premalignant lesions arising from the mucosa; adjuvant chemotherapy targets already-disseminated malignant cells, not future mucosal changes. |
| 3. It lowers tumor markers that stay high after surgery | After complete resection, tumor markers such as CEA typically fall. Adjuvant chemotherapy is not given primarily to normalize a persistently elevated marker; it is given to eliminate invisible residual disease even when markers are normal. |
| 4. It destroys unseen cancer cells that may remain | Correct. This directly describes eradication of micrometastases or MRD [1][2]. |

Key point! The rationale for adjuvant chemotherapy in stage III colon cancer is the presence of node-positive disease (N1), which implies a high probability of occult systemic spread. The goal is to treat minimal residual disease, not the primary tumor that was already removed [1][2].

Current guidelines support an oxaliplatin-based regimen such as FOLFOX (5-fluorouracil plus oxaliplatin) or CapeOx (capecitabine plus oxaliplatin) for stage III colon cancer [1]. Emerging tools such as circulating tumor DNA (ctDNA) are being studied to detect MRD after surgery and refine which patients truly need adjuvant therapy, but the fundamental principle remains: adjuvant chemotherapy targets residual disease that conventional imaging and pathology cannot see. [2]
References (research sources)

- [1]Adjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration.Research articlePaolo M Cruz J, George C Pales C, Min Kim K, Wan Kim Y (2018)

- [2]Circulating tumor DNA-based minimal residual disease-guided adjuvant therapy in solid tumors: Current evidence, clinical trial frameworks, and future directions.RCT/clinical trialMa M, Xia B, Xu Q, Chu J, Li S, Liu L. (2026) · DOI: 10.21147/j.issn.1000-9604.2026.04.06

## 임상 시나리오

Adjuvant Chemotherapy for Stage III Colon CancerWhy systemic treatment follows complete resection
Stage III colon cancer with N1 nodal involvement means cancer cells have already entered the lymphatic system. Even after complete surgical removal of visible tumor, micrometastases too small for imaging or pathology may remain in distant tissues.

The goal of adjuvant chemotherapy is to eradicate these occult cancer cells, reducing recurrence risk and improving cure rates. Clear surgical margins do not guarantee microscopic cure when nodes are positive.

CautionDo not confuse macroscopic complete resection with microscopic cure. Lymph node positivity is a marker that systemic spread has likely begun, so chemotherapy is indicated regardless of how complete the surgery appeared.

## 핵심 개념

- **Adjuvant chemotherapy** — Systemic treatment given after primary surgical resection to eliminate occult micrometastases and reduce recurrence risk.
- **Micrometastases** — Microscopic clusters of cancer cells that have spread beyond the primary tumor and are undetectable by routine imaging or pathology.
- **Stage III colon cancer** — Tumor invasion through the bowel wall with spread to regional lymph nodes (e.g., T3 N1 M0), indicating systemic risk.
- **N1** — Lymph node staging category indicating regional lymph node involvement by cancer cells.
- **Minimal residual disease** — Small numbers of cancer cells that remain after treatment and may lead to relapse if not eradicated.

## 같은 주제 문제

- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629730)
- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629731)
- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629732)
- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629733)
- [Situation: A 52-year-old woman has invasive ductal carcinoma of the left breast, stage IIB…](https://mymerci.kr/pages/nclex_q.php?qn_id=629734)
- [Situation: A 66-year-old man with adenocarcinoma of the lower rectum undergoes abdominoper…](https://mymerci.kr/pages/nclex_q.php?qn_id=629735)
- [Situation: A 66-year-old man with adenocarcinoma of the lower rectum undergoes abdominoper…](https://mymerci.kr/pages/nclex_q.php?qn_id=629736)
- [Situation: A 66-year-old man with adenocarcinoma of the lower rectum undergoes abdominoper…](https://mymerci.kr/pages/nclex_q.php?qn_id=629737)

---

More free questions: [기출문제](https://mymerci.kr/)

_학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요._